Drug Profile


Alternative Names: DPX-E7; HPV16-E711-19

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator Immunovaccine
  • Developer Dana-Farber Cancer Institute
  • Class Cancer vaccines; Viral vaccines
  • Mechanism of Action Human papillomavirus E7 protein modulators; Viral oncogene protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Anal cancer; Cervical cancer; Head and neck cancer

Most Recent Events

  • 21 Oct 2016 Phase-I/II clinical trials in Anal cancer in USA (SC)
  • 21 Oct 2016 Phase-I/II clinical trials in Cervical cancer in USA (SC)
  • 21 Oct 2016 Phase-I/II clinical trials in Head and neck cancer in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top